March 27th 2024
Investigators will assess the PRE-ACT tool’s ability to predict adverse effects such as skin and heart damage in a phase 3 trial.
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?
View More
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Abemaciclib Plus Endocrine Therapy Improved Survival in HR+/HER2– High-Risk Early Breast Cancer
December 7th 2022The prespecified overall survival analysis of the phase 3 monarchE trial when abemaciclib was added to endocrine therapy in patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer.
Integrative Oncology in Young Women With Breast Cancer
Yancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.
Camizestrant Meets PFS End Point Vs Fulvestrant in ER+ Advanced/Metastatic Breast Cancer
October 30th 2022Oral selective estrogen receptor degrader camizestrant elicited a statistically significant and clinically meaningful progression-free survival benefit compared with fulvestrant among patients with estrogen receptor–positive locally advanced or metastatic breast cancer.
ER Antagonist OP-1250 Demonstrates Continued Anti-Tumor Activity in Advanced ER+ HER2– Breast Cancer
October 29th 2022Among patients with advanced and/or metastatic hormone receptor–positive HER-2 negative breast cancer, complete estrogen receptor antagonist OP-1250 continued to yield clinical benefits such as reductions in target tumor lesions.
The Role of Trop-2 in mBC and the Rationale for Use of Trop-2–directed ADCs
October 20th 2022Dr Vidal elaborates on the role of trophoblast cell-surface antigen 2 (Trop-2) in metastatic breast cancer and discusses the rationale for using Trop-2–directed antibody-drug conjugates (ADCs), including sacituzumab govitecan (SG), in patients with the disease.
Article Introduction and HR+/HER2 mBC Background
October 20th 2022Sara Tolaney, MD, MPH introduces the 2022 Journal of Clinical Oncology preprint publication, “Sacituzumab Govitecan in Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer” and invites Martin Dietrich, MD, PhD and Gregory Vidal, MD, PhD to comment on the typical patients with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2-) metastatic breast cancer (mBC) who they see in their clinical practice.
Deborah Axelrod, MD, Discusses the Developments in the World of Breast Cancer Surgery
October 18th 2022As part of Breast Cancer Awareness Month, CancerNetwork® spoke with Deborah M. Axelrod, MD, about developments within the surgical breast cancer space, including decreasing the need for re-excision and full lymph node dissection.
Paolo Tarantino, MD, Spotlights Treatment Trends for Breast Cancer Awareness Month
October 12th 2022In an interview for Breast Cancer Awareness Month, Paolo Tarantino, MD, discusses the importance of multidisciplinary care for patients with breast cancer, the most exciting data presented this year, and prospects for future research.
FDA Grants Priority Review to Sacituzumab Govitecan-hziy in HR+/HER2– Advanced Breast Cancer
October 11th 2022Based on results from the phase 3 TROPiCS trial, the FDA has granted priority review to sacituzumab govitecan-hziy for unresectable locally advanced or metastatic hormone receptor–positive, HER2-negative breast cancer.
Kevin Kalinsky, MD, MS, Discusses Future Analyses of Ribociclib in HR+/HER2– Advanced Breast Cancer
October 10th 2022Kevin Kalinsky, MD, MS, spoke about future studies following results from the phase 2 MAINTAIN trial of ribociclib with or without endocrine therapy and after progression on a CDK4/6 inhibitor for patients with unresectable or metastatic hormone receptor–positive, HER2-negative breast cancer.